EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology

Jason R Brown, Guru Sonpavde

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-013213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jason R Brown und 1 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Immunotherapy, Biomarkers, Tumor. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While immune checkpoint inhibition (ICI) has revolutionized therapy across solid tumors, resistance remains an issue. Programmed death ligand-1 immunohistochemistry has limited clinical utility, whereas tumor mutation burden and microsatellite instability are only valuable for a minority of patients and leave room for improvement. Multiomic gene signatures have enhanced prediction of immune response by incorporating interferon-gamma signaling, T-cell dysfunction and exhaustion genes, and myeloid signatures. Single-cell RNA technology has been adopted to further optimize prediction of response to immunotherapy. A novel Immune Profile Score is presented by Zander et al that builds on prior immune signatures, using DNA and RNA profiling to predict outcomes across solid tumors receiving ICIs. While this assay is promising, further prospective validation and refinements will be necessary to realize its full potential in our quest to develop precision immuno-oncology. The incorporation of readily available clinical factors (eg, sites of metastasis), host genetics, orthogonal molecular platforms (microbiome, computational pathology, spatial transcriptomics, epigenetics, proteomics, radiomics) and investigating biomarkers to predict primary refractory disease and severe toxicities may further facilitate precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsImmunotherapyBiomarkers, TumorMedical OncologyImmune Checkpoint InhibitorsHumans

Stichwörter der Autor:innen

BiomarkerGene expression profiling - GEPImmunotherapy

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
  • Case Western Reserve University, Cleveland, Ohio, USA.
  • AdventHealth Cancer Institute, Orlando, Florida, USA guru.sonpavde.md@adventhealth.com.
  • University of Central Florida, Orlando, Florida, USA.

Zitieren

APA

Brown, J. R., & Sonpavde, G. (2025). Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013213

Vancouver

Brown JR, Sonpavde G. Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-013213

BibTeX
@article{Brown2025,
  author = {Brown, Jason R and Sonpavde, Guru},
  title = {Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-013213}
}
Kostenlos starten →